![]() |
Name |
6-O-methylaverufin
|
Molecular Formula | C21H18O7 | |
IUPAC Name* |
3,7-dihydroxy-9-methoxy-17-methyl-16,21-dioxapentacyclo[15.3.1.02,15.04,13.06,11]henicosa-2(15),3,6(11),7,9,13-hexaene-5,12-dione
|
|
SMILES |
COc1cc(O)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)C1CCCC(C)(O3)O1
|
|
InChI |
InChI=1S/C21H18O7/c1-21-5-3-4-13(27-21)17-14(28-21)8-11-16(20(17)25)19(24)15-10(18(11)23)6-9(26-2)7-12(15)22/h6-8,13,22,25H,3-5H2,1-2H3/t13-,21+/m1/s1
|
|
InChIKey |
DOWMCBYOVCRBEK-ASSNKEHSSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 382.37 | ALogp: | 3.2 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 102.3 | Aromatic Rings: | 5 |
Heavy Atoms: | 28 | QED Weighted: | 0.656 |
Caco-2 Permeability: | -5.229 | MDCK Permeability: | 0.00001630 |
Pgp-inhibitor: | 0.132 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.027 |
Blood-Brain-Barrier Penetration (BBB): | 0.002 | Plasma Protein Binding (PPB): | 95.27% |
Volume Distribution (VD): | 0.523 | Fu: | 12.32% |
CYP1A2-inhibitor: | 0.865 | CYP1A2-substrate: | 0.738 |
CYP2C19-inhibitor: | 0.086 | CYP2C19-substrate: | 0.077 |
CYP2C9-inhibitor: | 0.537 | CYP2C9-substrate: | 0.76 |
CYP2D6-inhibitor: | 0.384 | CYP2D6-substrate: | 0.4 |
CYP3A4-inhibitor: | 0.128 | CYP3A4-substrate: | 0.11 |
Clearance (CL): | 7.133 | Half-life (T1/2): | 0.477 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.486 |
Drug-inuced Liver Injury (DILI): | 0.965 | AMES Toxicity: | 0.656 |
Rat Oral Acute Toxicity: | 0.07 | Maximum Recommended Daily Dose: | 0.734 |
Skin Sensitization: | 0.863 | Carcinogencity: | 0.793 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.172 |
Respiratory Toxicity: | 0.644 |